Bio-link Australia Pty. Ltd.

22nd September 2015 – Deal Facilitated between TransBio and DendroCyte

Bio-Link has facilitated a Convertible License Agreement between TransBio Ltd and DendroCyte BioTech Pty Ltd for the Development of Antibody Drugs Targeting CD83 to prevent graft versus host disease. The License Agreement is the culmination of a multi-year collaboration to discover and develop novel antibody therapeutics directed against CD83, a relatively new cell surface drug target with the potential to be developed as a safe and efficacious therapy for the prophylaxis and treatment of graft versus host disease and other adverse immune reactions such as transplant rejection. Click here for the full press release.

TransBio-DendroCyte